As we approach 2026,late-stage programs across key therapeutic areas are poised to reshape treatment paradigms. Driven by novel mechanisms, first-in-class targets and more convenient administration ...
The analysis examined overall program counts as well as distribution by development stage, drug modality, and therapeutic area. Growth in early-stage development was observed across multiple countries ...
Biotechnology company Eikon Therapeutics announced the initial closing of a $350.7 million Series D financing round that it will use to advance its clinical-stage programs. The new funding brings the ...
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease ...
Hosted on MSN
Over the past decade, early-stage drug innovation has shifted toward China, researchers find
In 2015, about 48% of early-stage programs originated in the U.S. and 8% in China. By 2024, the U.S. share had declined to just over 37%, while China's share rose to just over 32%. Overall, the number ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results